1. Clinical & Scientific Overview
Pioglitazone Hydrochloride (TIP-MED-000055, Reference Code [4.11]) is classified under
Antidiabetic Medicines, Insulins & GLP-1 Agonists (Ch 04) as a Thiazolidinedione (TZD); Peroxisome Proliferator-Activated Receptor-Gamma (PPAR-gamma) Agonist (Insulin Sensitiser).
Within the Indian regulatory and compendial framework, it is governed under Schedule H & Schedule G Prescription Drug ('Caution: It is dangerous to take this preparation except under medical supervision' — Drugs Rules 1945).
Representative Indian Market Examples (Edition 2.7 Ch 04 [4.11], p. 50): Pioz (USV), Pioglar (Ranbaxy/Sun), Path (Lupin), Pglitz; In FDC with Metformin / Glimepiride: Pioz-MF, Tribet, Glycomet-Trio — Strengths & Dosage Forms: Oral Uncoated Tablets: 7.5 mg, 15 mg, 30 mg
Oral Uncoated Tablets: 7.5 mg, 15 mg, 30 mg
3. Mechanism of Action & Pharmacodynamics
Thiazolidinedione (TZD); Peroxisome Proliferator-Activated Receptor-Gamma (PPAR-gamma) Agonist (Insulin Sensitiser) acting on target receptor/enzyme pathways in Antidiabetic Medicines, Insulins & GLP-1 Agonists (Ch 04): clinical efficacy is mediated via Thiazolidinedione (TZD); Peroxisome Proliferator-Activated Receptor-Gamma (PPAR-gamma) Agonist (Insulin Sensitiser) for Type 2 diabetes mellitus with prominent insulin resistance (particularly with concurrent metabolic dysfunction-associated steatotic liver disease [MASLD/NASH]); secondary stroke prevention in insulin-resistant patients..
4. Therapeutic Indications & Evidence-Supported Uses
- Type 2 diabetes mellitus with prominent insulin resistance (particularly with concurrent metabolic dysfunction-associated steatotic liver disease [MASLD/NASH])
- secondary stroke prevention in insulin-resistant patients
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: General Adult Reference: Initially 7.5 mg to 15 mg once daily; may increase slowly to 30 mg once daily (in Indian clinical practice, 7.5 mg–15 mg OD is strongly preferred over 30–45 mg to minimise fluid retention and weight gain). Nuclear receptor transcription effect takes 6–12 weeks to reach full glycaemic reduction. Follow physician prescription.
Administration & Meal Timing: With or without food (take with meals if in FDC with metformin/glimepiride). | Once daily in the morning.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: Excreted primarily via bile/faeces; requires no pharmacokinetic dose adjustment in CKD, HOWEVER fluid retention and volume overload make pioglitazone hazardous in advanced CKD / nephrotic syndrome—use with extreme caution or avoid. Hepatic: Contraindicated if baseline ALT >2.5x ULN or in active hepatic disease.
Renal: Excreted primarily via bile/faeces; requires no pharmacokinetic dose adjustment in CKD, HOWEVER fluid retention and volume overload make pioglitazone hazardous in advanced CKD / nephrotic syndrome—use with extreme caution or avoid. Hepatic: Contraindicated if baseline ALT >2.5x ULN or in active hepatic disease.
Renal: Excreted primarily via bile/faeces; requires no pharmacokinetic dose adjustment in CKD, HOWEVER fluid retention and volume overload make pioglitazone hazardous in advanced CKD / nephrotic syndrome—use with extreme caution or avoid. Hepatic: Contraindicated if baseline ALT >2.5x ULN or in active hepatic disease.
7. Contraindications, Precautions & High-Risk Warnings
- Strictly CONTRAINDICATED in Congestive Heart Failure (NYHA Class I to IV—any history of heart failure!), active or historical bladder cancer, uninvestigated macroscopic haematuria, active liver disease (ALT >2.5x ULN), pregnancy, and diabetic ketoacidosis. High risk of distal extremity bone fractures in postmenopausal women.
Key Clinical Precautions: Renal: Excreted primarily via bile/faeces; requires no pharmacokinetic dose adjustment in CKD, HOWEVER fluid retention and volume overload make pioglitazone hazardous in advanced CKD / nephrotic syndrome—use with extreme caution or avoid. Hepatic: Contraindicated if baseline ALT >2.5x ULN or in active hepatic disease.
8. Adverse Effects Profile
- Sodium and water retention / peripheral pedal oedema (5–15%, climbing to >15% when combined with insulin), dose-dependent weight gain (2–4 kg via subcutaneous adipogenesis and fluid retention), mild dilutional anaemia (haemodilution), headache.
- Precipitation or acute decompensation of Congestive Heart Failure and pulmonary oedema, increased risk of urinary bladder carcinoma (with prolonged cumulative exposure >1–2 years), osteoporotic fractures of distal forearm/tibia/foot in women, macular oedema (blurred vision), rare hepatotoxicity.
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Metabolised primarily by CYP2C8: Gemfibrozil strongly inhibits CYP2C8 and triples pioglitazone AUC (avoid combination or reduce pioglitazone dose)
- Rifampicin induces CYP2C8 and reduces efficacy
- Co-administration with Insulin markedly increases the risk of severe oedema and heart failure
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: Inform the patient that pioglitazone takes 4 to 8 weeks to show its full sugar-lowering benefit. Instruct them to weigh themselves weekly and report immediately if they notice sudden weight gain (>2 kg in a week), ankle swelling, shortness of breath when lying flat, red/pink urine, or painful urination.
- Meal & Clock Timing Instruction: With or without food (take with meals if in FDC with metformin/glimepiride). (Once daily in the morning.)
- Missed Dose Protocol: Take as soon as remembered on the same day; skip if close to next day's dose.
- Geriatric Dispensing Pearl: Avoid in elderly CGHS patients with any history of heart failure, LV dysfunction, osteoporosis/fractures, or falls. Note that in India, pioglitazone is frequently hidden inside 'Triple FDCs' (Glimepiride + Metformin + Pioglitazone 7.5/15 mg, such as Glycomet-Trio or Tribet)—always inspect FDC composition if an elderly diabetic presents with unexplained leg swelling or breathlessness!
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Oral Uncoated Tablets: 7.5 mg, 15 mg, 30 mg
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 04 [4.11] (p. 50)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [4.5]-CMP12 Glibenclamide (Glyburide) IP — Second/Third-Generation Sulfonylurea; Pancreatic Beta-Cell Insuli
- [4.6]-CMP13 Glibenclamide (Glyburide) IP — Second-Generation Sulfonylurea with Selective Pancreatic SUR1 Bin
- [4.12]-CMP14 Voglibose IP — Alpha-Glucosidase Inhibitor; Intestinal Brush-Border Carbohydrate
- [4.13]-C15 Isophane (NPH) Human Insulin — Recombinant Human Peptide Hormone; Short-Acting (Regular), Interm